We are live on ! Find out more
GOSS icon

Gossamer Bio

120 hedge funds and large institutions have $225M invested in Gossamer Bio in 2022 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 35 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 35

19.1% more ownership

Funds ownership: 90.71%109.81% (+19%)

0% more call options, than puts

Call options by funds: $857K | Put options by funds: $857K

25% less funds holding

Funds holding: 160120 (-40)

65% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 60

78% less capital invested

Capital invested by funds: $1.02B → $225M (-$796M)

100% less funds holding in top 10

Funds holding in top 10: 50 (-5)

Holders
120
Holders Change
-40
Holders Change %
-25%
% of All Funds
1.93%
Holding in Top 10
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
New
21
Increased
50
Reduced
35
Closed
60
Calls
$857K
Puts
$857K
Net Calls
Net Calls Change
-$10.6M
Name Holding Trade Value Shares
Change
Change in
Stake
State Street
1
State Street
Massachusetts
$60.4M +$198M +24,066,082 +637%
Vanguard Group
2
Vanguard Group
Pennsylvania
$17.3M +$5.05M +613,694 +8%
BlackRock
3
BlackRock
New York
$11.7M -$783K -95,154 -2%
HA
4
HHLR Advisors
Cayman Islands
$10.8M -$20.1M -2,446,933 -33%
Millennium Management
5
Millennium Management
New York
$10M +$27.1M +3,296,396 +248%
WAM
6
Weiss Asset Management
Massachusetts
$7.91M +$7.16M +869,250 +31%
NMC
7
NEA Management Company
Maryland
$7.52M
BC
8
Boxer Capital
California
$7.24M -$1.93M -235,000 -7%
AG
9
Artal Group
Luxembourg
$7.04M
Morgan Stanley
10
Morgan Stanley
New York
$6.86M +$16.1M +1,955,742 +162%
Bank of America
11
Bank of America
North Carolina
$6.6M +$22.1M +2,685,828 +751%
Rafferty Asset Management
12
Rafferty Asset Management
New York
$6.01M +$20.9M +2,542,058 +1,108%
OCA
13
Octagon Capital Advisors
New York
$4.25M -$719K -87,373 -4%
Two Sigma Advisers
14
Two Sigma Advisers
New York
$3.96M +$7.88M +957,000 +110%
KCM
15
Kynam Capital Management
New Jersey
$3.84M +$11.4M +1,385,196 +359%
Goldman Sachs
16
Goldman Sachs
New York
$3.84M +$5.91M +717,305 +68%
UBS Group
17
UBS Group
Switzerland
$3.75M +$14M +1,699,439 +5,506%
Two Sigma Investments
18
Two Sigma Investments
New York
$3.17M +$4.42M +537,393 +58%
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$3.15M +$12M +1,453,740 New
Barclays
20
Barclays
United Kingdom
$3.11M +$10.5M +1,279,971 +839%
T. Rowe Price Associates
21
T. Rowe Price Associates
Maryland
$2.84M +$10.7M +1,298,783 +12,957%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$2.81M +$299K +36,345 +3%
Citigroup
23
Citigroup
New York
$2.62M +$1.07M +130,448 +12%
Marshall Wace
24
Marshall Wace
United Kingdom
$2.2M +$4.25M +515,894 +103%
JP Morgan Chase
25
JP Morgan Chase
New York
$1.99M +$6.96M +844,868 +1,162%

GOSS Hedge Fund Activity: Q4 2022 in Review

120 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q4 2022, worth a combined $225M — down 78% from $1.02B a quarter earlier.

Sellers outnumbered buyers: 60 funds closed out of GOSS and 21 opened new positions — a net loss of 39 holders — while 35 trimmed existing stakes and 50 added.

The largest buyer was State Street, adding an estimated $198M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $49.8M sold.

  • 120 institutional investors held Gossamer Bio (GOSS) as of Q4 2022, down from 160 in Q3 2022.
  • Funds reported $225M of Gossamer Bio stock for Q4 2022, down 78% quarter-over-quarter.
  • 21 funds opened new Gossamer Bio positions in Q4 2022 and 60 closed out, a net change of -39 holders.
  • The largest Gossamer Bio buyer in Q4 2022 was State Street, an estimated $198M added.
  • The largest Gossamer Bio seller in Q4 2022 was EcoR1 Capital, an estimated $49.8M sold.

Based on aggregated 13F filings for Q4 2022.